Retatrutide: Tri-Agonist Advancing in Phase 3 Clinical Trials | Retatrutide News

Retatrutide is a tri-agonist drug in Phase 3 trials targeting GIP, GLP-1, and glucagon receptors. Its development by Eli Lilly is significant for advanc...
Clinical Trials · October 29, 2026